Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

Analyst Ratings

Consensus Ratings for Imprimis Pharmaceuticals (NASDAQ:IMMY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Show:
DateFirmActionRatingPrice TargetActions
7/23/2015Sterne Agee CRTInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014CRT CapitalInitiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2014Craig HallumInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q415($0.26)($0.31)$3.52 million$3.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q3($0.38)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.25)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateHeadline
07/23/16 04:21 PMImprimis Pharmaceuticals : Peer-Reviewed Study of Dropless Cataract Surgery Shows `Measurable Benefits` Compared to Drops
07/22/16 08:02 AM9:02 am Imprimis Pharmaceuticals announces results of a clinical study comparing the efficacy of its injected triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin Dropless Therapy formulation to drops commonly prescribed after -
07/22/16 08:00 AMPeer-Reviewed Study of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared to Drops - [PR Newswire] - SAN DIEGO, July 22, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, today announced that positive results of a clinical study comparing the efficacy of its injected triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (Tri-Moxi-Vanc) Dropless Therapy® formulation to drops commonly prescribed after cataract surgery now appear in the July issue of the Journal of Clinical Ophthalmology. In this prospective, randomized, subject-masked contralateral eye study, 25 subjects with uncomplicated cataract received either Tri-Moxi-Vanc intraocular solution injected transzonularly into the vitreous or a topical formulation of prednisolone acetate, moxifloxacin hydrochloride and ketorolac tromethamine (Pred-Moxi-Ketor) for 1 week, followed by prednisolone acetate and ketorolac tromethamine (Pred-Ketor) for 2 to 4 weeks.
07/19/16 11:35 AMETF’s with exposure to Imprimis Pharmaceuticals, Inc. : July 19, 2016 -
06/17/16 04:26 PMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement -
06/15/16 05:08 AMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 07:30 AMImprimis Pharmaceuticals to Present at 6th Annual LD Micro Invitational on June 8, 2016 - [PR Newswire] - SAN DIEGO, June 3, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, today announced that its Chief Financial Officer, Andrew R. Boll, will present an update on the company's business at the 6th Annual LD Micro Invitational on Wednesday, June 8, 2016 at 2:00 p.m. (PDT) in Bel Air, Calif. Imprimis will also be hosting one-on-one meetings and attendees can contact their LD Micro representative to arrange a meeting. Imprimis Pharmaceuticals, Inc. (IMMY) is a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model. The company is focused on patient outcomes and affordability and offers high quality lower-cost custom compounded drugs in all 50 states. Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania.
06/01/16 04:58 PMExclusive: Meet One Pharma CEO Who's Doing Something To Bring Down Drug Prices - Benzinga recently had the chance to speak with Imprimis Pharmaceuticals Inc (NASDAQ: IMMY)’s Founder and CEO, Mark L. Baum J.D., one of the few guys in the pharma industry who’s doing something to fight drug price-gouging. Imprimis develops ...
06/01/16 11:25 AMImprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 07:30 AMImprimis Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference - [PR Newswire] - SAN DIEGO, June 1, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, ...
05/12/16 03:31 PMImprimis reports 1Q loss -
05/12/16 03:05 PMImprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update - [PR Newswire] - Imprimis now offers four unique proprietary antibiotic, steroid and nonsteroidal combination LessDrops formulations: Pred-Moxi, Pred-Ketor, Pred-Moxi-Ketor and the new Pred-Moxi-Nepafenac for use following cataract, LASIK, photorefractive keratectomy (PRK) and other ocular surgeries. Began dispensing the company's Tri-Mix and proprietary Tri-Mix-L formulations for erectile dysfunction to one of the largest managed healthcare organizations in the U.S. Imprimis currently offers tiopronin delayed-release (DR) formulations available in customizable doses including 200mg and 250mg capsules, and tiopronin-K DR, which is comprised of tiopronin along with potassium citrate for those patients who have had their potassium citrate dosing titrated.
05/12/16 03:03 PMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition -
05/12/16 07:30 AMClinical Study of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction in Cystoid Macular Edema in Patients Following Cataract Surgery - [PR Newswire] - SAN DIEGO, May 12, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, today announced the positive results of an investigator-initiated clinical study presented at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, relating to the company's triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (Tri-Moxi-Vanc) Dropless Therapy® formulation. The purpose of the study was to prospectively compare rates of post-operative CME using traditional steroid and NSAID drops with Dropless Therapy, (intravitreal Tri-Moxi-Vanc) combined with an NSAID drop. A total of 1,200 consecutive cataract surgeries were monitored for CME prospectively for 90 days post-op, excluding cases with pre-operative CME. The results of the study revealed the CME rate was 1.5% in the historical group (n= 600) using NSAID and steroid drops post operatively. The CME rate was 0.5% in the group (n=600) receiving Dropless Therapy (intravitreal Tri-Moxi-Vanc) with post-operative NSAID drops only, thereby achieving statistical significance (P=0.003) in CME prevention versus traditional steroid and NSAID drops.
05/12/16 06:07 AMQ1 2016 Imprimis Pharmaceuticals Inc Earnings Release - After Market Close -
05/11/16 03:25 PMInvestor Calendar Invites You to the Imprimis Pharmaceuticals First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016 - [Accesswire] - SAN DIEGO, CA / ACCESSWIRE / May 11, 2016 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, ...
05/05/16 07:30 AMImprimis Pharmaceuticals Announces Plans to Launch IV Free™ Conscious Sedation and New Compounded Triple Drop Formulations at Leading Cataract and Refractive Surgeons Meeting - [PR Newswire] - SAN DIEGO, May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free™ MKO Melt™ conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016. A co-developer of the MKO Melt, John Berdahl, MD, stated, "It is one of the best things we have done for the patient experience, not to mention the surgeon and nurses experience. I love the predictable level of sedation." In a recent article published in Ophthalmology Management, Dr. Berdahl added that less time struggling to start IVs means he can perform an extra surgery or two per day.
05/04/16 07:30 AMImprimis Pharmaceuticals to Host its First Quarter 2016 Financial Report Conference Call and Webcast on May 12, 2016 at 4:30 p.m. EDT - [PR Newswire] - Imprimis Pharmaceuticals, Inc. (IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's two business programs, Imprimis Cares™ and Custom Compounding Choice™, focus on patient outcomes and affordability by offering high quality custom compounded drugs in all 50 states. Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania.
05/02/16 07:30 AMImprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola® - [PR Newswire] - SAN DIEGO, May 2, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced the availability of the company's new patent-pending customizable delayed-release (DR) tiopronin formulations as a lower-cost therapeutic alternative to FDA-approved Thiola®. Thiola, FDA-approved as a 100mg tablet, is composed of tiopronin as its sole active drug ingredient and is commonly prescribed for the prevention of cystine kidney stone formation in patients who do not respond to dietary changes and increased fluids. Physicians and their cystinuria patients may now choose from one of two lower-cost compounded alternatives to Thiola. Tiopronin DR, which is comprised of the active ingredient tiopronin along with a cellulose-based FDA-approved delayed release agent. This formulation is available in various customizable doses including 200mg and 250mg capsules.
04/26/16 04:02 PMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an -
04/12/16 06:30 AMImprimis Pharmaceuticals Registers its Texas Facility with the FDA as an Outsourcing Facility - [PR Newswire] - SAN DIEGO, April 12, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, announced today that it has filed for registration of its ImprimisRx TX pharmacy, located in Allen, Texas, with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The Drug Quality and Security Act (DQSA), signed into law on November 27, 2013, created this pathway in which a compounding pharmacy can voluntarily register with the FDA as an outsourcing facility under Section 503B of the federal Food, Drug and Cosmetic Act, comply with the DQSA and avail itself of the operational benefits the law provides.
04/11/16 04:22 PMEdited Transcript of IMMY earnings conference call or presentation 23-Mar-16 8:30pm GMT -
04/05/16 04:26 PMETF’s with exposure to Imprimis Pharmaceuticals, Inc. : April 5, 2016 -
02/10/16 08:00 AMImprimis Pharmaceuticals to Make a Lower Cost Compounded and Customizable Alternative to Thiola® - [PR Newswire] - SAN DIEGO, Feb. 10, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug ...
02/07/16 01:50 PMCall Martin Shkreli Whatever You Want, But Not A Pharma CEO - Forbes - ForbesCall Martin Shkreli Whatever You Want, But Not A Pharma CEOForbesIt took just a few weeks for another company, Imprimis Pharmaceuticals (IMMY), to announce they would bring a compounded formula of the drug to market. The response was harsh and swift, and the attention brought by the controversy appears to have led ...and more »
02/04/16 04:43 PMVideo-Rising Cost of Drugs for Imprimis Pharmaceuticals, Inc. -
02/03/16 01:47 PMImprimis Pharmaceuticals, Inc. (IMMY) - Imprimis Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing proprietary compounded drug therapies to physicians and patients in the United States. The company owns, markets, and sells a portfolio of proprietary ...
01/28/16 01:37 PMLatest Analysts Reports On Imprimis Pharmaceuticals, Inc. (IMMY) - Risers & Fallers - Latest Analysts Reports On Imprimis Pharmaceuticals, Inc. (IMMY)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Imprimis Pharmaceuticals, Inc. (IMMY). The latest broker reports which have been released state 0 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts ...and more »
01/26/16 01:36 PMA New Prescription for Lower Drug Prices - But the drug’s small market meant it faced no generic competition, creating the opportunity Turing exploited. Imprimis Pharmaceuticals, IMMY 2.22 % the company I run, quickly brought to market a 99-cent pill containing the identical dosage of FDA ...
01/26/16 12:36 AM[$$] A New Prescription for Lower Drug Prices -
01/25/16 07:01 AMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F -
01/22/16 12:37 PM5 Pharmaceuticals Stocks to Sell Now - Investorplace.com - 5 Pharmaceuticals Stocks to Sell NowInvestorplace.comThis week, Imprimis Pharmaceuticals, Inc.'s (IMMY) rating worsens to a D from the company's C rating a week ago. Imprimis Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of non-invasive topically ...and more »
01/06/16 05:15 AMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure -
12/28/15 04:06 PMIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater -
12/17/15 03:13 PMImprimis, a Turing rival, aims to undercut drug price hikes -
12/17/15 10:14 AMImprimis Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/17/15 07:30 AMImprimis Pharmaceuticals Announces National Account Agreement with the Cataract & Laser Institute - [PR Newswire] - SAN DIEGO and FORT WAYNE, Ind., Dec. 17, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, and Cataract & Laser Institute, a leading provider of refractive and cataract surgery, today announced they have entered into a national account agreement to provide Imprimis' Dropless Cataract Therapy™ to patients at the Cataract & Laser Institute. Randal K. Hughes, MD, Drew Davis, MD, Kuumba Long, MD and Stephen Kruse, MD of the Cataract & Laser Institute stated, "As leading providers of ophthalmic care, we are pleased to offer Dropless Cataract Therapy™ to help our patients eliminate or reduce the number of eye drops required to be administered following cataract surgery.
12/11/15 07:30 AMImprimis Pharmaceuticals Reports Results of Independent Third Party Potency Analysis of its Compounded Pyrimethamine and Leucovorin Capsules - [PR Newswire] - SAN DIEGO, Dec. 11, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug ...
12/08/15 12:17 PMIMPRIMIS PHARMACEUTICALS, INC. Financials -
12/08/15 08:31 AMHIV Diagnoses Are Falling -
12/02/15 08:30 AMGibraltar Industries, Macy, Express Scripts Holding, Imprimis Pharmaceuticals and Valeant Pharmaceuticals highlighted as Zacks Bull and Bear of the Day -
12/02/15 07:15 AMImprimis Pharmaceuticals (IMMY) Jumps: Stock Rises 10.6% -
12/01/15 01:57 PMTuring hit again by competition -
12/01/15 01:51 PMExpress Scripts (ESRX) Stock Gains, Prices HIV Drug at $1 Per Pill -
12/01/15 01:24 PMExpress Scripts offers low-cost alternative to Turing drug -

Social

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMMY
  • CUSIP:
Key Metrics:
  • Previous Close: $3.90
  • 50 Day Moving Average: $3.8594
  • 200 Day Moving Average: $4.2168
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $51.89M
  • Beta: -0.9
  • Current Year EPS Consensus Estimate: $-0.94 EPS
  • Next Year EPS Consensus Estimate: $-0.42 EPS
Additional Links:
Imprimis Pharmaceuticals (NASDAQ:IMMY) Chart for Friday, July, 29, 2016